Skip to main content
Top
Published in: Osteoporosis International 8/2015

01-08-2015 | Original Article

Impact of interactive voice response technology on primary adherence to bisphosphonate therapy: a randomized controlled trial

Authors: A. D. Cizmic, R. M. F. Heilmann, J. L. Milchak, C. S. Riggs, S. J. Billups

Published in: Osteoporosis International | Issue 8/2015

Login to get access

Abstract

Summary

Osteoporosis (weak bones) is a disorder that has high morbidity, mortality, and healthcare utilization. Effective treatment is available for this disorder, but many patients choose not to start therapy. This is the first study showing an intervention that increases the initiation rates to medications for osteoporosis.

Introduction

One out of six patients prescribed an oral bisphosphonate does not initiate therapy, a phenomenon known as primary non-adherence. Reasons for bisphosphonate primary non-adherence have been identified, but not interventions that positively impact primary adherence rates. The purpose of this study is to determine the effectiveness of interactive voice response technology to improve oral bisphosphonate primary adherence.

Methods

This was a prospective, randomized controlled trial conducted in January–December 2014 at Kaiser Permanente Colorado, an integrated healthcare system. Adults with a new oral bisphosphonate prescription for osteoporosis or osteopenia which was not purchased within 14–20 days of being ordered were included. There were 127 and 118 patients in the intervention group and control groups, respectively. The intervention group received an interactive voice response phone call followed by a letter 1 week later if primary non-adherence continued, whereas the control group did not receive any outreach. The primary outcome was the proportion of patients who purchased their oral bisphosphonate within 25 days of randomization.

Results

There were 62/127 (48.8 %) intervention patients and 36/118 (30.5 %) control patients who purchased their bisphosphonate prescription within 25 days of randomization (OR = 2.17, 95 % CI 1.29–3.67). When adjusted for age, sex, history of bone mineral density scan and fracture, the odds ratio for intervention versus control group was 2.3 (95 % CI 1.34–3.94).

Conclusion

An interactive voice response phone call and follow-up letter significantly improved primary adherence to oral bisphosphonate therapy. Such an intervention could be considered for improving primary adherence rates to other medication classes.
Appendix
Available only for authorised users
Literature
2.
go back to reference Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348(9041):1535–1541PubMedCrossRef Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348(9041):1535–1541PubMedCrossRef
3.
go back to reference Andrade SE, Majumdar SR, Chan KA, Buist DS, Go AS, Goodman M, Smith DH, Platt R, Gurwitz JH (2003) Low frequency of treatment of osteoporosis among postmenopausal women following a fracture. Arch Intern Med 163:2052–2057PubMedCrossRef Andrade SE, Majumdar SR, Chan KA, Buist DS, Go AS, Goodman M, Smith DH, Platt R, Gurwitz JH (2003) Low frequency of treatment of osteoporosis among postmenopausal women following a fracture. Arch Intern Med 163:2052–2057PubMedCrossRef
4.
go back to reference Yood RA, Mazar KM, Andrade SE, Emani S, Chan W, Kahler KH (2008) Patient decision to initiate therapy for osteoporosis: the influence of knowledge and beliefs. J Gen Intern Med 23(11):1815–1821PubMedCentralPubMedCrossRef Yood RA, Mazar KM, Andrade SE, Emani S, Chan W, Kahler KH (2008) Patient decision to initiate therapy for osteoporosis: the influence of knowledge and beliefs. J Gen Intern Med 23(11):1815–1821PubMedCentralPubMedCrossRef
5.
go back to reference Gadkari AS, McHorney CA (2010) Medication nonfulfillment rates and reasons: narrative systematic review. Curr Med Res Opin 26:683–705PubMedCrossRef Gadkari AS, McHorney CA (2010) Medication nonfulfillment rates and reasons: narrative systematic review. Curr Med Res Opin 26:683–705PubMedCrossRef
6.
go back to reference Hogan KN, Milchak JL, Heilmann RMF, Billups SJ, Delate T (2013) Evaluation of primary nonadherence to oral bisphosphonate therapy. J Am Geriatr Soc 61(11):2046–2047PubMedCrossRef Hogan KN, Milchak JL, Heilmann RMF, Billups SJ, Delate T (2013) Evaluation of primary nonadherence to oral bisphosphonate therapy. J Am Geriatr Soc 61(11):2046–2047PubMedCrossRef
7.
go back to reference Derose SF, Green K, Marrett E, Tunceli K, Cheetham TC, Chiu VY, Harrison TN, Reynolds K, Vansomphone SS, Scott RD (2013) Automated outreach to increase primary adherence to cholesterol-lowering medications. JAMA Intern Med 173(1):38–43PubMedCrossRef Derose SF, Green K, Marrett E, Tunceli K, Cheetham TC, Chiu VY, Harrison TN, Reynolds K, Vansomphone SS, Scott RD (2013) Automated outreach to increase primary adherence to cholesterol-lowering medications. JAMA Intern Med 173(1):38–43PubMedCrossRef
8.
go back to reference Sale JE, Gignac MA, Hawker G, Frankel L, Beaton D, Bogoch E, Elliot-Gibson V (2011) Decision to take osteoporosis medication in patients who have had a fracture and are ‘high’ risk for future fracture: a qualitative study. BMC Musculoskelet Disord 12:92PubMedCentralPubMedCrossRef Sale JE, Gignac MA, Hawker G, Frankel L, Beaton D, Bogoch E, Elliot-Gibson V (2011) Decision to take osteoporosis medication in patients who have had a fracture and are ‘high’ risk for future fracture: a qualitative study. BMC Musculoskelet Disord 12:92PubMedCentralPubMedCrossRef
9.
go back to reference Schousboe JT, Dowd BE, Davison ML, Kane RL (2010) Association of medication attitudes with non-persistence and non-compliance with medication to prevent fractures. Osteoporos Int 21:1899–1909PubMedCrossRef Schousboe JT, Dowd BE, Davison ML, Kane RL (2010) Association of medication attitudes with non-persistence and non-compliance with medication to prevent fractures. Osteoporos Int 21:1899–1909PubMedCrossRef
10.
go back to reference Penning-van Beest FJA, Erkens JA, Olson M, Herings RMC (2008) Loss of treatment benefit due to low compliance with bisphosphonate therapy. Osteoporos Int 19:511–517PubMedCentralPubMedCrossRef Penning-van Beest FJA, Erkens JA, Olson M, Herings RMC (2008) Loss of treatment benefit due to low compliance with bisphosphonate therapy. Osteoporos Int 19:511–517PubMedCentralPubMedCrossRef
11.
go back to reference Fenerty SD, West C, Davis SA, Kaplan SG, Feldman SR (2012) The effect of reminder systems on patients’ adherence to treatment. Patient Prefer Adherence 6:127–135PubMedCentralPubMed Fenerty SD, West C, Davis SA, Kaplan SG, Feldman SR (2012) The effect of reminder systems on patients’ adherence to treatment. Patient Prefer Adherence 6:127–135PubMedCentralPubMed
12.
go back to reference Delmas PD, Vrijens B, Eastell R, Roux C, Pols HA, Ringe JD, Grauer A, Cahall D, Watts NB, Improving Measurements of Persistence on Actonel Treatment (IMPACT) Investigators (2007) Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 92(4):1296–1304PubMedCrossRef Delmas PD, Vrijens B, Eastell R, Roux C, Pols HA, Ringe JD, Grauer A, Cahall D, Watts NB, Improving Measurements of Persistence on Actonel Treatment (IMPACT) Investigators (2007) Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 92(4):1296–1304PubMedCrossRef
13.
go back to reference Clowes JA, Peel NF, Eastell R (2004) The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 89(3):1117–1123PubMedCrossRef Clowes JA, Peel NF, Eastell R (2004) The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 89(3):1117–1123PubMedCrossRef
14.
go back to reference Cramer JA, Amonkar MM, Hebborn A, Altman R (2005) Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 21(9):1453–1460PubMedCrossRef Cramer JA, Amonkar MM, Hebborn A, Altman R (2005) Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 21(9):1453–1460PubMedCrossRef
15.
go back to reference Recker RR, Gallagher R, MacCosbe PE (2005) Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 80(7):856–861PubMedCrossRef Recker RR, Gallagher R, MacCosbe PE (2005) Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 80(7):856–861PubMedCrossRef
16.
go back to reference Karter AJ, Parker MM, Moffet HH, Ahmed AT, Schmittdiel JA, Selby JV (2009) New prescription medication gaps: a comprehensive measure of adherence to new prescriptions. Health Serv Res 44(5):1640–1661PubMedCentralPubMedCrossRef Karter AJ, Parker MM, Moffet HH, Ahmed AT, Schmittdiel JA, Selby JV (2009) New prescription medication gaps: a comprehensive measure of adherence to new prescriptions. Health Serv Res 44(5):1640–1661PubMedCentralPubMedCrossRef
17.
go back to reference Liberman JN, Hutchins DS, Popiel RG, Patel MH, Jan SA, Berger JE (2010) Determinants of primary nonadherence in asthma-controller and dyslipidemia pharmacotherapy. Am J Pharm Benefits 2(2):111–118 Liberman JN, Hutchins DS, Popiel RG, Patel MH, Jan SA, Berger JE (2010) Determinants of primary nonadherence in asthma-controller and dyslipidemia pharmacotherapy. Am J Pharm Benefits 2(2):111–118
18.
go back to reference Wright NC, Looker AC, Saag KG, Curtis JR, Delzell ES, Randall S, Dawson-Hughes B (2014) The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine. J Bone Miner Res 29(11):2520–2526PubMedCrossRef Wright NC, Looker AC, Saag KG, Curtis JR, Delzell ES, Randall S, Dawson-Hughes B (2014) The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine. J Bone Miner Res 29(11):2520–2526PubMedCrossRef
Metadata
Title
Impact of interactive voice response technology on primary adherence to bisphosphonate therapy: a randomized controlled trial
Authors
A. D. Cizmic
R. M. F. Heilmann
J. L. Milchak
C. S. Riggs
S. J. Billups
Publication date
01-08-2015
Publisher
Springer London
Published in
Osteoporosis International / Issue 8/2015
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-015-3116-z

Other articles of this Issue 8/2015

Osteoporosis International 8/2015 Go to the issue